KK2260 + KK2260
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors
Trial Timeline
Nov 1, 2023 → Apr 30, 2030
NCT ID
NCT06248411About KK2260 + KK2260
KK2260 + KK2260 is a phase 1 stage product being developed by Kyowa Kirin for Advanced or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06248411. Target conditions include Advanced or Metastatic Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06248411 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors